Targeted therapy for medullary and extramedullary relapse of FLT3-ITD acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation
| Autor: | Hiroaki Kakutani, Hirokazu Tanaka, Shoko Nakayama, Shuji Minamoto, Shinya Rai, Yosaku Watatani, Itaru Matsumura, Yasuyoshi Morita, Yasuhiro Taniguchi, J. Luis Espinoza, Takahiro Kumode, Takashi Ashida |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
FLT3-ITD
Medullary cavity medicine.medical_treatment Gilteritinib Hematopoietic stem cell transplantation lcsh:RC254-282 Article Targeted therapy 03 medical and health sciences 0302 clinical medicine immune system diseases hemic and lymphatic diseases Myeloid sarcoma Medicine Acute myeloid leukemia business.industry Myeloid leukemia Hematology medicine.disease lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens surgical procedures operative Oncology 030220 oncology & carcinogenesis Cancer research Complete Molecular Response business 030215 immunology Flt3 itd |
| Zdroj: | Leukemia Research Reports, Vol 14, Iss, Pp 100219-(2020) Leukemia Research Reports |
| ISSN: | 2213-0489 |
| Popis: | We report a case with extramedullary tumors affecting the supraclavicular region that presented as a relapse of acute myeloid leukemia (AML) with FLT3-ITD mutation after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Treatment with gilteritinib resulted in remarkable response with disappearance of both the medullary and extramedullary tumors. Subsequently, a 2nd allo-HSCT was performed in an attempt to cure his AML and complete molecular response has been sustained with gilteritinib resumption without worsening GVHD. Targeted therapy with gilteritinib for medullary and extramedullary relapse of FLT3-ITD AML could be effective and suitable as a bridging therapy for allo-HSCT. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|